I am an MD pathology resident...few months left for final exams. Give a short notes on parapeoteins
- Goldman-Cecil Medicine, 22e; Robbins & Kumar Basic Pathology
| Component | Normal Role | Paraprotein Relevance |
|---|---|---|
| Heavy chains (IgG, IgA, IgM, IgD, IgE) | Determine Ig class | Determines M protein type |
| Light chains (kappa κ, lambda λ) | Associate with heavy chains | Free light chains = Bence Jones protein |
| Free light chains | Minor amount in serum | Markedly elevated in myeloma/AL amyloidosis |
- Goldman-Cecil Medicine, Table 173-1
| Feature | Threshold |
|---|---|
| Serum M protein | < 3 g/dL |
| Clonal plasma cells in bone marrow | < 10% |
| Absence of | Myeloma-defining events, amyloidosis, macroglobulinemia |
| Risk Group | Features | 20-yr progression risk |
|---|---|---|
| Low | M protein <1.5 g/dL, IgG subtype, normal FLC ratio (0.26-1.65) | 5% |
| Low-intermediate | 1 abnormal factor | 21% |
| High-intermediate | 2 abnormal factors | 37% |
| High | All 3 factors abnormal | 58% |
- Goldman-Cecil Medicine, Table 173-3
| Type | Frequency |
|---|---|
| IgG | ~60% |
| IgA | ~20-25% |
| Light chain only (κ or λ) | ~15-20% |
| IgD, IgE, IgM | Rare |
- Tietz Textbook of Laboratory Medicine, 7th ed.; Quick Compendium of Clinical Pathology, 5th ed.
| System | Manifestation | Mechanism |
|---|---|---|
| Kidney | Cast nephropathy (myeloma kidney) | Bence Jones protein casts + tubular toxicity |
| Kidney | AL amyloidosis | Light chain deposition as fibrils |
| Kidney | Light chain deposition disease | Non-amyloid linear deposits |
| Nerves | MGUS-associated neuropathy | Unclear; anti-MAG antibodies in IgM MGUS |
| Nerves | AL amyloid neuropathy | Amyloid infiltration |
| Nerves | CIDP-like | IgM/IgG paraprotein-associated CIDP |
| Bone | Lytic lesions | RANKL/osteoclast activation |
| Skin | Necrobiotic xanthogranuloma | IgG paraprotein deposition |
| Skin | EED (Erythema elevatum diutinum) | IgA paraprotein association |
| Blood | Hyperviscosity syndrome | IgM > IgA > IgG (size/polymerization) |
| Blood | Cryoglobulinemia | Ig precipitate at low temp |
| Blood | Platelet dysfunction | Masking of surface receptors |
| Blood | Acquired vWD | Adsorption of high-MW vWF multimers |
| Type | Composition | Disease Association |
|---|---|---|
| Type I | Monoclonal Ig only (IgM or IgG) | Myeloma, Waldenström - hyperviscosity |
| Type II | Monoclonal IgM (RF) + polyclonal IgG | HCV (most common), autoimmune |
| Type III | Polyclonal IgM + polyclonal IgG | Autoimmune, chronic infections |
90% have monoclonal Ig detectable by IFE (serum or urine) or FLC assay
| Letter | Feature |
|---|---|
| P | Polyneuropathy (progressive, sensorimotor) |
| O | Organomegaly (hepato/splenomegaly, lymphadenopathy) |
| E | Endocrinopathy (multiple) |
| M | M protein (usually IgA or IgG, λ light chain) |
| S | Skin changes (hyperpigmentation, hemangiomata, hypertrichosis) |
| Feature | MGUS | Smoldering Myeloma | Multiple Myeloma |
|---|---|---|---|
| M protein | <3 g/dL | ≥3 g/dL | Any level |
| Marrow plasma cells | <10% | 10-60% | >10% (often >30%) |
| Symptoms | None | None | CRAB criteria |
| Lytic lesions | Absent | Absent | Present |
| Anemia/renal/Ca | Absent | Absent | Present (CRAB) |
| Progression risk | 1%/yr | ~10%/yr | N/A (already malignant) |